Logo

Teva’s Ranivisio (biosimilar, ranibizumab) Receives EC’s Approval for Retinal Diseases

Share this

Teva’s Ranivisio (biosimilar, ranibizumab) Receives EC’s Approval for Retinal Diseases

Shots:

  • The EC has granted the marketing authorization for Ranivisio, a biosimilar to Lucentis for adults across 5 indications incl. AMD, visual impairment due to macular oedema secondary to RVO, visual impairment resulting from DME, PDR, and CNV
  • The P-III (COLUMBUS-AMD) study showed that ranibizumab was shown to be highly similar to its reference ranibizumab in terms of clinical efficacy, ocular and systemic safety for AMD and other ophthalmology indications
  • Teva & Bioeq AG collaborated for the exclusive commercialization of ranibizumab and the product is expected to be available in the EU over the coming year while the treatment is already available in the UK under the tradename Ongavia

Ref: Businesswire | Image: Teva

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions